(Med-TechNews, December 12, 2022).

Sir Nicholas Wright and Digistain in the UK has created a new tool to aid the early detection of breast cancer. Based on clinical trials, this new development is helping those eligible successfully avoid chemotherapy through earlier and more personalized test results. This allows patients more time to make decisions, less anxiety, and more specific treatment plans. Not only that, but fewer chemo treatments and associated side effects allows an estimated 30% in savings for health providers. This tool will soon be adopted in the USA starting with investors from the Y Combinator and Harvard University.

New “revolutionary” AI breast cancer diagnostic launched – Med-Tech Innovation (med-technews.com)